Corynoxine B derivative CB6 prevents Parkinsonian toxicity in mice by inducing PIK3C3 complex-dependent autophagy

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Autophagy impairment is implicated in neurodegenerative diseases like Parkinson's disease (PD).
• Corynoxine B (Cory B) induces neuronal autophagy but has low brain permeability, limiting its therapeutic potential for PD.
• Developing brain-permeable autophagy inducers is crucial for PD treatment.

Purpose of the Study:

• To evaluate the autophagy-enhancing and neuroprotective effects of a novel Cory B derivative, CB6.
• To investigate the mechanism of action of CB6 in promoting autophagy.
• To assess the efficacy of CB6 in preclinical models of Parkinson's disease.

Main Methods:

• CB6's effect on autophagy flux was assessed in N2a neural cells.
• Neuroprotection by CB6 against MPP+-induced apoptosis in PC12 cells was evaluated.
• The efficacy of CB6 was tested in an MPTP-induced mouse model of PD, assessing motor function and dopaminergic neuron survival.

Main Results:

• CB6 dose-dependently increased autophagy flux in neural cells by activating the PIK3C3 complex and promoting PI3P production.
• CB6 protected PC12 cells from MPP+-induced apoptosis by enhancing autophagy.
• Oral administration of CB6 in mice significantly improved motor deficits and prevented dopaminergic neuron loss in PD models.

Conclusions:

• Compound CB6 is a potent, brain-permeable autophagy enhancer that acts via PIK3C3 complex activation.
• CB6 demonstrates significant neuroprotective effects against Parkinson's disease pathology in vitro and in vivo.
• CB6 holds potential as a therapeutic agent for the prevention or treatment of Parkinson's disease.